Compare Stocks: IMCR, CGON, MIRM, and ORKA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CGON CG Oncology	$74.62 -1.3%	$74.06	$35.64 ▼ $80.97	$6.61B	0.24	665,333 shs	1.78 million shs
IMCR Immunocore	$32.00 -0.9%	$34.68	$27.56 ▼ $40.71	$1.65B	0.74	329,650 shs	475,904 shs
MIRM Mirum Pharmaceuticals	$91.83 -7.1%	$103.81	$63.23 ▼ $130.00	$5.96B	0.49	532,173 shs	1.80 million shs
ORKA Oruka Therapeutics	$94.96 -2.8%	$96.40	$14.89 ▼ $115.51	$6.29B	-0.34	746,357 shs	1.94 million shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CGON CG Oncology	0.00%	+3.14%	-3.85%	+22.17%	+97.83%
IMCR Immunocore	0.00%	-1.84%	-11.80%	+11.89%	-4.25%
MIRM Mirum Pharmaceuticals	0.00%	-6.51%	-5.40%	-14.28%	+25.55%
ORKA Oruka Therapeutics	0.00%	+2.79%	-9.44%	+31.27%	+485.81%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CGON CG Oncology	$74.62 -1.3%	$74.06	$35.64 ▼ $80.97	$6.61B	0.24	665,333 shs	1.78 million shs
IMCR Immunocore	$32.00 -0.9%	$34.68	$27.56 ▼ $40.71	$1.65B	0.74	329,650 shs	475,904 shs
MIRM Mirum Pharmaceuticals	$91.83 -7.1%	$103.81	$63.23 ▼ $130.00	$5.96B	0.49	532,173 shs	1.80 million shs
ORKA Oruka Therapeutics	$94.96 -2.8%	$96.40	$14.89 ▼ $115.51	$6.29B	-0.34	746,357 shs	1.94 million shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CGON CG Oncology	0.00%	+3.14%	-3.85%	+22.17%	+97.83%
IMCR Immunocore	0.00%	-1.84%	-11.80%	+11.89%	-4.25%
MIRM Mirum Pharmaceuticals	0.00%	-6.51%	-5.40%	-14.28%	+25.55%
ORKA Oruka Therapeutics	0.00%	+2.79%	-9.44%	+31.27%	+485.81%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CGON CG Oncology	2.73	Moderate Buy	$87.78	17.63% Upside
IMCR Immunocore	2.58	Moderate Buy	$56.38	76.17% Upside
MIRM Mirum Pharmaceuticals	2.93	Moderate Buy	$137.31	49.53% Upside
ORKA Oruka Therapeutics	2.82	Moderate Buy	$133.00	40.06% Upside

Current Analyst Ratings Breakdown

Latest IMCR, CGON, MIRM, and ORKA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/3/2026	ORKA Oruka Therapeutics	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$120.00
9/3/2026	IMCR Immunocore	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
9/3/2026	ORKA Oruka Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$120.00
8/27/2026	MIRM Mirum Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$137.00
8/27/2026	MIRM Mirum Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
8/27/2026	MIRM Mirum Pharmaceuticals	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform	$137.00
8/24/2026	IMCR Immunocore	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/21/2026	IMCR Immunocore	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$50.00
8/11/2026	ORKA Oruka Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$200.00
8/11/2026	ORKA Oruka Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$165.00
8/11/2026	ORKA Oruka Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$151.00

(Data available from 9/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CGON CG Oncology	$4.04M	1,637.21	N/A	N/A	$9.33 per share	8.00
IMCR Immunocore	$400.02M	4.12	N/A	N/A	$7.52 per share	4.26
MIRM Mirum Pharmaceuticals	$521.31M	11.44	$0.05 per share	1,801.33	$6.12 per share	15.00
ORKA Oruka Therapeutics	N/A	N/A	N/A	N/A	$9.69 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CGON CG Oncology	-$160.99M	-$2.69	N/A	N/A	N/A	-3,602.68%	-25.20%	-23.98%	11/13/2026 (Estimated)
IMCR Immunocore	-$35.51M	-$0.37	N/A	128.00	N/A	-4.20%	-4.54%	-1.66%	11/5/2026 (Estimated)
MIRM Mirum Pharmaceuticals	-$23.36M	-$14.55	N/A	N/A	N/A	-139.18%	-36.28%	-8.54%	11/3/2026 (Estimated)
ORKA Oruka Therapeutics	-$105.43M	-$2.03	N/A	N/A	N/A	N/A	-21.65%	-20.88%	11/11/2026 (Estimated)

Latest IMCR, CGON, MIRM, and ORKA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/10/2026	Q2 2026	ORKA Oruka Therapeutics	-$0.5125	-$0.55	-$0.0375	-$0.55	N/A	N/A
8/7/2026	Q2 2026	IMCR Immunocore	-$0.01	-$0.02	-$0.01	-$0.02	$148.57 million	N/A
8/6/2026	Q2 2026	CGON CG Oncology	-$0.6642	-$0.90	-$0.2359	-$0.90	$0.36 million	$1.16 million
8/5/2026	Q2 2026	MIRM Mirum Pharmaceuticals	-$0.7425	-$1.06	-$0.3175	-$1.06	$166.33 million	$176.24 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CGON CG Oncology	N/A	N/A	N/A	N/A	N/A
IMCR Immunocore	N/A	N/A	N/A	N/A	N/A
MIRM Mirum Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ORKA Oruka Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CGON CG Oncology	N/A	22.22	22.20
IMCR Immunocore	0.94	4.47	4.44
MIRM Mirum Pharmaceuticals	1.28	2.86	2.74
ORKA Oruka Therapeutics	N/A	38.51	38.51

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CGON CG Oncology	26.56%
IMCR Immunocore	84.50%
MIRM Mirum Pharmaceuticals	N/A
ORKA Oruka Therapeutics	56.44%

Insider Ownership

Company	Insider Ownership
CGON CG Oncology	4.80%
IMCR Immunocore	10.10%
MIRM Mirum Pharmaceuticals	8.32%
ORKA Oruka Therapeutics	23.49%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CGON CG Oncology	142	88.64 million	84.39 million	Optionable
IMCR Immunocore	524	51.50 million	46.30 million	Optionable
MIRM Mirum Pharmaceuticals	433	64.93 million	59.53 million	Optionable
ORKA Oruka Therapeutics	68	66.21 million	50.66 million	N/A

IMCR, CGON, MIRM, and ORKA Headlines

Recent News About These Companies

Insider Selling: Oruka Therapeutics (NASDAQ:ORKA) CEO Sells $234,680.92 in Stock

September 18 at 6:29 AM | americanbankingnews.com

Arjun Agarwal Sells 9,459 Shares of Oruka Therapeutics (NASDAQ:ORKA) Stock

September 17 at 4:38 AM | americanbankingnews.com

Joana Goncalves Sells 7,947 Shares of Oruka Therapeutics (NASDAQ:ORKA) Stock

September 17 at 4:38 AM | americanbankingnews.com

Oruka Therapeutics (NASDAQ:ORKA) SVP Sells 560 Shares

September 16, 2026 | insidertrades.com

Oruka Therapeutics (NASDAQ:ORKA) SVP Arjun Agarwal Sells 560 Shares of Stock

September 15, 2026 | marketbeat.com

Lawrence Otto Klein Sells 2,452 Shares of Oruka Therapeutics (NASDAQ:ORKA) Stock

September 15, 2026 | marketbeat.com

Oruka Therapeutics (NASDAQ:ORKA) Insider Joana Goncalves Sells 7,947 Shares of Stock

September 15, 2026 | marketbeat.com

Oruka Therapeutics (NASDAQ:ORKA) SVP Sells 9,459 Shares of Stock

September 15, 2026 | marketbeat.com

Oruka (ORKA): EVERLAST-A 28+ Week Data Key Catalyst For ORKA-001 In Psoriasis

September 15, 2026 | rttnews.com

Oruka Therapeutics, Inc. (NASDAQ:ORKA) Given Average Recommendation of "Moderate Buy" by Brokerages

September 13, 2026 | americanbankingnews.com

Oruka Therapeutics, Inc. (NASDAQ:ORKA) Given Average Rating of "Moderate Buy" by Brokerages

September 13, 2026 | marketbeat.com

Analysts Are Bullish on Top Healthcare Stocks: Oruka Therapeutics (ORKA), Jazz Pharmaceuticals (JAZZ)

September 10, 2026 | theglobeandmail.com

Oruka Therapeutics to Attend the 2026 Morgan Stanley Global Healthcare Conference

September 9, 2026 | globenewswire.com

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Grows Stock Holdings in Oruka Therapeutics, Inc. $ORKA

September 7, 2026 | marketbeat.com

Q3 EPS Estimate for Oruka Therapeutics Lowered by Analyst

September 7, 2026 | marketbeat.com

Legal & General Group Plc Purchases Shares of 30,198 Oruka Therapeutics, Inc. $ORKA

September 6, 2026 | marketbeat.com

HC Wainwright Reiterates "Buy" Rating for Oruka Therapeutics (NASDAQ:ORKA)

September 3, 2026 | marketbeat.com

278,164 Shares in Oruka Therapeutics, Inc. $ORKA Acquired by Braidwell LP

September 3, 2026 | marketbeat.com

Insider Selling: Oruka Therapeutics (NASDAQ:ORKA) CEO Sells 75,000 Shares of Stock

September 2, 2026 | insidertrades.com

Bank of New York Mellon Corp Invests $13.41 Million in Oruka Therapeutics, Inc. $ORKA

September 2, 2026 | marketbeat.com

Oruka Therapeutics (NASDAQ:ORKA) CEO Lawrence Otto Klein Sells 75,000 Shares

September 1, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMCR, CGON, MIRM, and ORKA Company Descriptions

CG Oncology NASDAQ:CGON

$74.62 -1.00 (-1.32%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$72.49 -2.13 (-2.85%)

As of 09/18/2026 07:30 PM Eastern

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.

Immunocore NASDAQ:IMCR

$32.00 -0.30 (-0.93%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$31.83 -0.17 (-0.53%)

As of 09/18/2026 07:30 PM Eastern

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

Mirum Pharmaceuticals NASDAQ:MIRM

$91.83 -6.99 (-7.07%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$92.88 +1.05 (+1.14%)

As of 09/18/2026 07:30 PM Eastern

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.

Oruka Therapeutics NASDAQ:ORKA

$94.96 -2.77 (-2.83%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$95.00 +0.04 (+0.04%)

As of 09/18/2026 07:30 PM Eastern

Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IMCR, CGON, MIRM, and ORKA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IMCR, CGON, MIRM, and ORKA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IMCR, CGON, MIRM, and ORKA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMCR, CGON, MIRM, and ORKA Company Descriptions

CG Oncology NASDAQ:CGON

Immunocore NASDAQ:IMCR

Mirum Pharmaceuticals NASDAQ:MIRM

Oruka Therapeutics NASDAQ:ORKA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IMCR, CGON, MIRM, and ORKA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IMCR, CGON, MIRM, and ORKA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IMCR, CGON, MIRM, and ORKA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMCR, CGON, MIRM, and ORKA Company Descriptions

CG Oncology NASDAQ:CGON

Immunocore NASDAQ:IMCR

Mirum Pharmaceuticals NASDAQ:MIRM

Oruka Therapeutics NASDAQ:ORKA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools